ArticleWorld journal of psychiatry2026
Clinical efficacy of Xifeng Huashi and its effect on mental status in patients with diarrheal irritable bowel.
Article in World journal of psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiarrheal irritable bowel syndrome (IBS-D) is a functional gastrointestinal disorder characterized by abdominal pain accompanied by recurrent diarrhea that significantly impacts the quality of life and mental health of patients.
aimTo investigate the clinical efficacy of Xifeng Huashi and its effects on the mental status of patients diagnosed with IBS-D.
methodsData from 128 patients with IBS-D treated at the Nanjing University of Chinese Medicine Affiliated Hospital of Integrated Traditional Chinese and Western Medicine between June 2023 and May 2024 were divided into control and research groups, with 64 patients in each group. The control group received conventional treatment with Western medicine alone, whereas the research group was prescribed Xifeng Huashi. Differences in specific indices between the two groups were observed and compared using relevant assessment tools.
resultsThe research group showed a higher total effective rate (92.19%
conclusionXifeng Huashi is effective for the treatment of IBS-D and manifests advantages in improving clinical symptoms and mental status, as well as reducing the short-term relapse rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.